EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effectiveness and Safety of Personalized Cholic Acid Treatment in Patients With Bile Acid Synthesis Defects

Yasmin Polak iD, Elles Marleen Kemper iD, Marc Engelen iD, Femke C C Klouwer iD, Kevin Berendse, Frédéric M Vaz iD, Bart G P Koot iD, Eleonora Noortje L Swart, Carla E M Hollak iD

Journal of Inherited Metabolic Disease · 2025

DOI: 10.1002/jimd.70062 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Inherited Metabolic Disease, 2025. Verfasst von Yasmin Polak und 8 weiteren Autor:innen. Beteiligte Einrichtung: Platform Medicine for Society, Amsterdam, the Netherlands. Hauptthemen laut MEDLINE: Cholic Acid, Bile Acids and Salts. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nationale Postcode Loterij.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bile acid synthesis defects (BASDs) comprise a group of rare, often severe, metabolic disorders. Bile acid replacement therapy decreases toxic bile acid intermediates production and improves biochemical profiles, potentially delaying or stabilizing disease progression. An open label, non‐randomized trial with cholic acid (CA) supplementation included six patients with α‐methylacyl‐CoA racemase (AMACR) deficiency and one patient with 3β‐hydroxy‐Δ 5 ‐C 27 ‐steroid oxidoreductase deficiency. Patients received up to 20 mg/kg/day CA for 3.5 years, adjusted for biochemical response, side effects, and clinical evaluation. Bile acid metabolites, liver enzymes, liver stiffness, and neurological symptoms were evaluated at baseline and during follow‐up. CA was well tolerated in children ( n = 3), allowing for higher doses. Adults ( n = 4) experienced more side effects, primarily diarrhea and other gastrointestinal symptoms. Children's transaminase levels normalized during treatment, while adults' levels remained normal throughout. Elevated C 27 ‐bile acid intermediates, C 29 ‐dicarboxylic acid, and pristanic acid were observed in all AMACR patients. C 27 ‐bile acids and C 29 ‐dicarboxylic acid decreased with treatment, while pristanic acid fluctuated and remained elevated. No clinically relevant changes were observed in liver elasticity, fat‐soluble vitamin levels, neurological assessment, or growth (in children). One adult developed hepatocellular carcinoma during treatment. CA treatment is generally safe, with acceptable tolerance and a marked biochemical response observed in children, although biomarker levels remained markedly elevated. In adults, however, the balance shifts negatively, with side effects outweighing the (biochemical) benefits. A longer study is necessary to evaluate the impact of CA treatment on the clinical relevance of the observed biochemical response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cholic AcidBile Acids and SaltsHumansMaleFemaleChildAdultChild, PreschoolAdolescentTreatment OutcomeYoung AdultPrecision MedicineInfantLiver

Stichwörter der Autor:innen

3β‐hydroxy‐Δ5‐C27‐steroid oxidoreductase (3β‐HSD)bile acid synthesischolic acidperoxisomal disordersingle enzyme defectstoxic bile acid intermediatesα‐methylacyl‐CoA racemase (AMACR)

Substanzen

Cholic AcidBile Acids and Salts

Autor:innen und Institutionen

  • Platform Medicine for Society, Amsterdam, the Netherlands.
  • Department of Pharmacy and Clinical Pharmacology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
  • Department of Pediatric Neurology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
  • The Pediatric Practice (de Kinderartsenpraktijk), Amsterdam, the Netherlands.
  • Department of Laboratory Medicine and Pediatrics, Laboratory Genetic Metabolic Diseases, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
  • Department of Pediatric Gastroenterology, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.

ORCID-Profile: Yasmin Polak, Elles Marleen Kemper, Marc Engelen, Femke C C Klouwer, Frédéric M Vaz, Bart G P Koot, Carla E M Hollak

Förderung

  • Nationale Postcode Loterij

Zitieren

APA

Polak, Y., Kemper, E. M., Engelen, M., Klouwer, F. C. C., Berendse, K., Vaz, F. M., Koot, B. G. P., Swart, E. N. L., & Hollak, C. E. M. (2025). Effectiveness and Safety of Personalized Cholic Acid Treatment in Patients With Bile Acid Synthesis Defects. Journal of Inherited Metabolic Disease. https://doi.org/10.1002/jimd.70062

Vancouver

Polak Y, Kemper EM, Engelen M, Klouwer FCC, Berendse K, Vaz FM, et al. Effectiveness and Safety of Personalized Cholic Acid Treatment in Patients With Bile Acid Synthesis Defects. Journal of Inherited Metabolic Disease. 2025. doi:10.1002/jimd.70062

BibTeX
@article{Polak2025,
  author = {Polak, Yasmin and Kemper, Elles Marleen and Engelen, Marc and Klouwer, Femke C C and Berendse, Kevin and Vaz, Frédéric M and Koot, Bart G P and Swart, Eleonora Noortje L and Hollak, Carla E M},
  title = {Effectiveness and Safety of Personalized Cholic Acid Treatment in Patients With Bile Acid Synthesis Defects},
  journal = {Journal of Inherited Metabolic Disease},
  year = {2025},
  doi = {10.1002/jimd.70062}
}
Kostenlos starten →